Tmunity Therapeutics to Sell to Kite
Palo Alto – December 22, 2022 – Cooley advised Tmunity, a clinical-stage biotechnology company, on its agreement to sell to Kite, a global biopharmaceutical company. Partners Mark Weeks, Ben Beerle and Marya Postner led the Cooley team.
The acquisition will provide Kite with pre-clinical and clinical programs, as well as an ‘armored’ chimeric antigen receptor (CAR) T technology platform – which can be applied to a variety of CAR T-cell therapies to enhance anti-tumor activity – and processes for rapid manufacture of CAR T-cell therapies. Tmunity’s prostate-specific membrane antigen and prostate stem cell antigen assets are not part of the Kite acquisition and will be spun out by Tmunity before the closing and as part of the transaction.
Headquartered in Philadelphia, Tmunity is focused on transforming the future of CAR T-cell therapies by developing the next generation of engineered T-cell treatments, innovative manufacturing processes and technologies.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has nearly 1,500 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.